Clinical experiment designed to assess clinical efficacy targeting ID in human. Primary outcome: Validate Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease
Description
Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease
Background and Rationale
The ubiquitin-proteasome system (UPS) is a critical cellular quality control mechanism responsible for degrading misfolded proteins. Mounting evidence suggests UPS dysfunction plays a pivotal role in Parkinson's disease (PD) pathogenesis, particularly in α-synuclein aggregation and dopaminergic neurodegeneration. This multi-phase translational study aims to validate UPS dysfunction as a primary driver of PD pathology through comprehensive molecular, cellular, and clinical investigations. The study employs a novel approach combining advanced proteomics, functional assays, and biomarker validation to establish causative relationships between UPS impairment and disease progression. Phase I utilizes induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PD patients and controls to characterize UPS dysfunction mechanisms. Phase II involves longitudinal analysis of cerebrospinal fluid and plasma biomarkers in early-stage PD patients, correlating UPS activity with clinical progression....
Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease
Background and Rationale
The ubiquitin-proteasome system (UPS) is a critical cellular quality control mechanism responsible for degrading misfolded proteins. Mounting evidence suggests UPS dysfunction plays a pivotal role in Parkinson's disease (PD) pathogenesis, particularly in α-synuclein aggregation and dopaminergic neurodegeneration. This multi-phase translational study aims to validate UPS dysfunction as a primary driver of PD pathology through comprehensive molecular, cellular, and clinical investigations. The study employs a novel approach combining advanced proteomics, functional assays, and biomarker validation to establish causative relationships between UPS impairment and disease progression. Phase I utilizes induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PD patients and controls to characterize UPS dysfunction mechanisms. Phase II involves longitudinal analysis of cerebrospinal fluid and plasma biomarkers in early-stage PD patients, correlating UPS activity with clinical progression. Phase III tests UPS-targeting therapeutic interventions in patient-derived cellular models. Key innovations include real-time UPS activity monitoring using fluorescent degron reporters, quantitative mass spectrometry analysis of ubiquitin chain topology, and development of UPS-specific biomarkers for clinical application. The study addresses critical knowledge gaps regarding temporal relationships between UPS dysfunction and α-synuclein pathology, identifies novel therapeutic targets within the UPS pathway, and establishes clinically relevant biomarkers for disease monitoring and drug development.
This experiment directly tests predictions arising from the following hypotheses:
Heat Shock Protein 70 Disaggregase Amplification
VCP-Mediated Autophagy Enhancement
HSP90-Tau Disaggregation Complex Enhancement
Lysosomal Enzyme Trafficking Correction
Low Complexity Domain Cross-Linking Inhibition
Experimental Protocol
Phase I (Months 1-18): Generate iPSC-derived dopaminergic neurons from 50 PD patients (25 sporadic, 25 familial with SNCA/LRRK2/PRKN mutations) and 25 age-matched controls. Perform UPS activity assays using fluorogenic substrates (Suc-LLVY-AMC), quantify 26S proteasome assembly by native PAGE, and measure ubiquitin chain dynamics via mass spectrometry. Assess α-synuclein aggregation using thioflavin-T binding and immunofluorescence microscopy at 14, 21, and 28 days post-differentiation. Phase II (Months 12-48): Recruit 200 early-stage PD patients (Hoehn-Yahr stage 1-2) and 100 controls for longitudinal biomarker study. Collect CSF and plasma samples every 6 months for 3 years. Quantify proteasome subunit levels (PSMA7, PSMB5), ubiquitin conjugates, and α-synuclein species using ELISA and Simoa assays. Correlate biomarkers with MDS-UPDRS scores, DaTscan results, and cognitive assessments. Phase III (Months 24-42): Test UPS modulators (proteasome activators PA28γ, deubiquitinase inhibitors) in patient iPSC neurons. Measure rescue of UPS function, α-synuclein clearance, and neuronal viability using ATP-based assays and caspase-3/7 activity. Statistical analysis includes mixed-effects models for longitudinal data, correlation analysis for biomarker relationships, and ANOVA for treatment comparisons with Bonferroni correction.
Expected Outcomes
1. PD patient-derived neurons will show 40-60% reduction in proteasome activity compared to controls (p<0.001), with SNCA mutation carriers showing greatest impairment.
2. Longitudinal CSF analysis will reveal 2-3 fold elevation in polyubiquitin conjugates and 30% reduction in 26S proteasome levels in PD patients versus controls at 18-month follow-up.
3. UPS dysfunction biomarkers will correlate with disease progression rate (r=0.6-0.8) and predict 12-month MDS-UPDRS score changes with 75% accuracy.
4. Proteasome activator treatment will restore UPS activity to 80% of control levels and reduce α-synuclein aggregates by 50% in patient neurons.
5. A 3-biomarker panel (PSMB5, K48-ubiquitin, α-synuclein oligomers) will discriminate PD from controls with 85% sensitivity and 90% specificity.
6. UPS dysfunction severity will inversely correlate with dopamine transporter binding (r=-0.7) and predict cognitive decline progression.
Success Criteria
• Demonstrate statistically significant UPS dysfunction in ≥80% of PD patient-derived neuronal cultures with effect size >0.8
• Establish temporal relationship showing UPS impairment precedes α-synuclein aggregation by ≥7 days in cellular models
• Achieve biomarker panel AUC >0.85 for PD diagnosis with cross-validation across independent cohorts
• Show significant correlation (r>0.6, p<0.01) between UPS biomarkers and clinical progression over 24-month follow-up
• Demonstrate therapeutic rescue with UPS modulators improving neuronal survival by ≥30% and reducing aggregates by ≥40%
• Validate findings across ≥3 independent patient cohorts with consistent effect directions and significance levels p<0.05
TARGET GENE
ID
MODEL SYSTEM
human
ESTIMATED COST
$6,550,000
TIMELINE
49 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease
Phase I (Months 1-18): Generate iPSC-derived dopaminergic neurons from 50 PD patients (25 sporadic, 25 familial with SNCA/LRRK2/PRKN mutations) and 25 age-matched controls. Perform UPS activity assays using fluorogenic substrates (Suc-LLVY-AMC), quantify 26S proteasome assembly by native PAGE, and measure ubiquitin chain dynamics via mass spectrometry. Assess α-synuclein aggregation using thioflavin-T binding and immunofluorescence microscopy at 14, 21, and 28 days post-differentiation. Phase II (Months 12-48): Recruit 200 early-stage PD patients (Hoehn-Yahr stage 1-2) and 100 controls for longitudinal biomarker study. Collect CSF and plasma samples every 6 months for 3 years.
...
Phase I (Months 1-18): Generate iPSC-derived dopaminergic neurons from 50 PD patients (25 sporadic, 25 familial with SNCA/LRRK2/PRKN mutations) and 25 age-matched controls. Perform UPS activity assays using fluorogenic substrates (Suc-LLVY-AMC), quantify 26S proteasome assembly by native PAGE, and measure ubiquitin chain dynamics via mass spectrometry. Assess α-synuclein aggregation using thioflavin-T binding and immunofluorescence microscopy at 14, 21, and 28 days post-differentiation. Phase II (Months 12-48): Recruit 200 early-stage PD patients (Hoehn-Yahr stage 1-2) and 100 controls for longitudinal biomarker study. Collect CSF and plasma samples every 6 months for 3 years. Quantify proteasome subunit levels (PSMA7, PSMB5), ubiquitin conjugates, and α-synuclein species using ELISA and Simoa assays. Correlate biomarkers with MDS-UPDRS scores, DaTscan results, and cognitive assessments. Phase III (Months 24-42): Test UPS modulators (proteasome activators PA28γ, deubiquitinase inhibitors) in patient iPSC neurons. Measure rescue of UPS function, α-synuclein clearance, and neuronal viability using ATP-based assays and caspase-3/7 activity. Statistical analysis includes mixed-effects models for longitudinal data, correlation analysis for biomarker relationships, and ANOVA for treatment comparisons with Bonferroni correction.
Expected Outcomes
1. PD patient-derived neurons will show 40-60% reduction in proteasome activity compared to controls (p<0.001), with SNCA mutation carriers showing greatest impairment.
2. Longitudinal CSF analysis will reveal 2-3 fold elevation in polyubiquitin conjugates and 30% reduction in 26S proteasome levels in PD patients versus controls at 18-month follow-up.
3. UPS dysfunction biomarkers will correlate with disease progression rate (r=0.6-0.8) and predict 12-month MDS-UPDRS score changes with 75% accuracy.
4.
...
1. PD patient-derived neurons will show 40-60% reduction in proteasome activity compared to controls (p<0.001), with SNCA mutation carriers showing greatest impairment.
2. Longitudinal CSF analysis will reveal 2-3 fold elevation in polyubiquitin conjugates and 30% reduction in 26S proteasome levels in PD patients versus controls at 18-month follow-up.
3. UPS dysfunction biomarkers will correlate with disease progression rate (r=0.6-0.8) and predict 12-month MDS-UPDRS score changes with 75% accuracy.
4. Proteasome activator treatment will restore UPS activity to 80% of control levels and reduce α-synuclein aggregates by 50% in patient neurons.
5. A 3-biomarker panel (PSMB5, K48-ubiquitin, α-synuclein oligomers) will discriminate PD from controls with 85% sensitivity and 90% specificity.
6. UPS dysfunction severity will inversely correlate with dopamine transporter binding (r=-0.7) and predict cognitive decline progression.
Success Criteria
• Demonstrate statistically significant UPS dysfunction in ≥80% of PD patient-derived neuronal cultures with effect size >0.8
• Establish temporal relationship showing UPS impairment precedes α-synuclein aggregation by ≥7 days in cellular models
• Achieve biomarker panel AUC >0.85 for PD diagnosis with cross-validation across independent cohorts
• Show significant correlation (r>0.6, p<0.01) between UPS biomarkers and clinical progression over 24-month follow-up
• Demonstrate therapeutic rescue with UPS modulators improving neuronal survival by ≥30% and reducing aggregates by ≥40%
•
...
• Demonstrate statistically significant UPS dysfunction in ≥80% of PD patient-derived neuronal cultures with effect size >0.8
• Establish temporal relationship showing UPS impairment precedes α-synuclein aggregation by ≥7 days in cellular models
• Achieve biomarker panel AUC >0.85 for PD diagnosis with cross-validation across independent cohorts
• Show significant correlation (r>0.6, p<0.01) between UPS biomarkers and clinical progression over 24-month follow-up
• Demonstrate therapeutic rescue with UPS modulators improving neuronal survival by ≥30% and reducing aggregates by ≥40%
• Validate findings across ≥3 independent patient cohorts with consistent effect directions and significance levels p<0.05